Wedbush Rates Climb Bio (CLYM) buy, $17 Price Target
Wedbush has reaffirmed its buy rating on Climb Bio, setting a price target of $17, as the stock trades at $10.71, a 58.73% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wedbush rated Climb Bio, Inc. ($CLYM) "buy" with a $17 price target on June 12, 2026.
Since the rating, $CLYM is up 6.5% after 1 week, up 15.5% after 1 month and down 14.2% to date (from the $11.44 close on Jun 12, 2026).
CLYM
Climb Bio, Inc.
Key Points
- Wedbush reiterated its buy rating on Climb Bio, Inc. with a target price of $17, while the stock is currently priced at $10.71.
- The stock trades significantly below its 52-week high of $18.33, suggesting potential upside as analysts remain positive.
- Climb Bio, a biotechnology firm, is focused on developing therapies for immune-mediated diseases and has a market cap of about $783 million.
Get $CLYM trade alerts by text
We text you when insiders, Congress or big funds trade $CLYM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Climb Bio, Inc. alert may contain errors. Disclosures
Wedbush Maintains Buy Rating
On June 12, 2026, Wedbush reiterated its buy rating on Climb Bio, Inc. (CLYM) with a price target of $17. The stock is currently trading at $10.71 on the NasdaqGM exchange.
What Changed in Wedbush's View
Wedbush has kept its price target steady at $17 after previously rating the stock as a buy. The firm continues to see value in Climb Bio, given its focus on unmet medical needs in the biotechnology sector.
Analysts Set New Price Targets
Several analysts have also provided insights into Climb Bio. On September 8, 2026, Oppenheimer maintained an outperform rating with a target of $25, up from $18. HC Wainwright & Co. also kept its buy rating, raising the target from $24 to $30. B. Riley Securities reiterated its buy rating, increasing its target from $26 to $30. BTIG maintained a buy rating with a new target of $32, up from $20. These ratings suggest a strong consensus among analysts regarding the stock's potential.
How Climb Bio, Inc. Stock Has Traded
Climb Bio's shares are currently trading at $10.71, which is well below its 52-week high of $18.33. This low trading price might attract investors looking for potential growth, especially since the stock has a 50-day moving average of $14.25. The market has seen fluctuations, but analysts remain optimistic about its future performance.
$CLYM price target
Climb Bio, Inc. daily closes and this analyst's $17 target. Not advice.
Recent Earnings
Climb Bio, Inc. reported an EPS of -0.82, indicating a net loss. The company has a forward P/E ratio of -13.6, reflecting its current lack of profitability. Climb Bio is set to report its next earnings on November 13, 2026, which could provide further insights into its financial health and operational progress.
What Climb Bio, Inc. Does
Climb Bio, Inc. is a clinical-stage biotechnology company based in Wellesley Hills, Massachusetts. The company is focused on developing therapies for immune-mediated diseases, including its lead product candidate, budoprutug. This focus aligns with the growing demand for innovative treatments in the healthcare sector.
What's Ahead for Climb Bio, Inc.
Investors will be watching Climb Bio closely as it prepares for its next earnings report in November. The reaffirmation of the buy rating by Wedbush and other analysts indicates that the market has high expectations for the company's future developments. Remember, the latest analyst ratings reflect views as of June 12, 2026, and may not represent current market conditions.
Related Filing Alerts
Source: Wedbush's rating change on $CLYM (Jun 12, 2026). Written by software, not financial advice. How we make alerts